TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24807339
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 micrograms every 4 hours after 800 micrograms vaginal loading dose)
Study: 24807339
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 micrograms every 3 hours after 800 micrograms vaginal loading dose)
Study: 20560409
Drug: Group training
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group training (90-min sessions, twice a week for 12 weeks)
Study: 15315964
Drug: ABVD +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD + RT (6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine followed by radiation therapy)
Study: 10903600
Drug: Beta-blockers (propranolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (propranolol)
Study: 9291744
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine adrenaline tetracaine (LAT gel)
Study: 3518526
Drug: Cladosporium herbarum
Normalized name: CLADOSPORIUM HERBARUM
DrugBank: Cladosporium herbarum (DB10865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladosporium herbarum preparation
Study: 30962230
Drug: Internet cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet cognitive behavioural therapy (iCBT) fixed-order stress management (intervention group B)
Study: 21338801
Drug: bovine somatotropin
Normalized name: Bovine somatotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: bovine somatotropin (bST) treatment
Study: 10218362
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment (2 ml, three times a day for three days)
Study: 2141743
Drug: Ibuprofen as
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen as a supplement to conservative treatment
Study: 2141743
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as a supplement to conservative treatment
Study: 158003
Drug: Powder face
Normalized name: TITANIUM DIOXIDE 0.212 kg in 1 kg / ZINC OXIDE 0.15 kg in 1 kg TOPICAL POWDER [Larkly SPF30 Mineral Powder Face Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder face mask with 1.19% clindamycin phosphate in 70% ethanol applied once daily for 5 days
Study: 158003
Drug: Solution with
Normalized name: LVP solution with potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution with 1.19% clindamycin phosphate in 70% ethanol applied once daily for 5 days
Study: 158003
Drug: Powder face
Normalized name: TITANIUM DIOXIDE 0.212 kg in 1 kg / ZINC OXIDE 0.15 kg in 1 kg TOPICAL POWDER [Larkly SPF30 Mineral Powder Face Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder face mask without clindamycin phosphate applied once daily for 5 days
Study: 31350270
Drug: peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: peficitinib 100 mg once daily
Study: 31350270
Drug: peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: peficitinib 150 mg once daily
Study: 23504137
Drug: Multi‐modality adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi‐modality adjuvant therapy
Study: 23504137
Drug: Single‐modality adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐modality adjuvant therapy
Study: 21503263
Drug: Tiotropium (a
Normalized name: tiotropium (as bromide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (a once‐daily inhaled anticholinergic)
Study: 19364166
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) 240 mg x d(‐1)
Study: 14657447
Drug: Semantic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic treatment
Study: 14657447
Drug: Phonological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological treatment
Study: 9988898
Drug: AMO 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMO 2 x 1000 mg/day (group A)
Study: 9988898
Drug: ACA 2
Normalized name: Rubraca 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACA 2 x 1250 mg/day (group B)
Study: 9988898
Drug: OME +
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OME + AZI treatment
Study: 2718921
Drug: Diet providing
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet providing 1 g ascorbic acid/d
Study: 2718921
Drug: Diet limiting
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet limiting ascorbic acid to about 20 mg/d
Study: 25969531
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of antituberculosis therapy using intermittent directly observed therapy (DOTs)
Study: 25969531
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of antituberculosis therapy using intermittent directly observed therapy (DOTs)
Study: 23342782
Drug: Medication (Valaciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Valaciclovir Hydrochlordide and vitamin B1)
Study: 20891044
Drug: Cernilton (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernilton (two doses, specific dosages not mentioned)
Study: 15857084
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment after hand instrumentation
Study: 8562664
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous clomipramine infusion
Study: 8562664
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral clomipramine treatment
Study: 8562664
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who worsened after clomipramine infusion
Study: 31585544
Drug: FENO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO group (asthma treatment guided by FENO plus symptoms)
Study: 31585544
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care group (asthma treatment guided by symptoms only)
Study: 19397224
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (daily combination of vitamin E 800 IU, vitamin C 250 mg, vitamin B6 100 mg, vitamin B12 250 mcg, folic acid 10 mg) for 8 weeks
Study: 16856571
Drug: Nicorandil (NCR)
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (NCR) administered intravenously (4 mg) via intracoronary injection (2 mg) or continuously (4 mg/h) in poor flow patients.
Study: 16856571
Drug: Nicorandil (NCR)
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (NCR) administered in good flow patients.
Study: 9251423
Drug: 1 gm
Normalized name: Ifex 1 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm P2AM single bolus dose at admission followed by placebo infusion over the next 4 days
Study: 9251423
Drug: 12 gm
Normalized name: Carimune 12 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 gm P2AM as a continuous infusion over the next 4 days
Study: 20495585
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam (2 mg)
Study: 1531383
Drug: Epidural methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural methyl prednisolone (80 mg)
Study: 6088395
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g intravenous immunoglobulin divided into three doses per therapy course for infection prophylaxis (Group A)
Study: 6088395
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group B) receiving identical chemoradiotherapy without immunoglobulin therapy
Study: 23891275
Drug: Metformin 1000mg
Normalized name: METFORMIN 1000MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000mg daily
Study: 16723884
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (loading 10 mg/kg followed by 30 mg/kg daily)
Study: 16723884
Drug: Nimodipine (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (48 mg/d)
Study: 8481256
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative therapy
Study: 28206674
Drug: SCS-ON (Spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCS-ON (Spinal Cord Stimulation, 50 Hz, 210-μs pulse duration, 12 hours daily)
Study: 25898052
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (67.5 mg)
Study: 25898052
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (22.5 mg)
Study: 25898052
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (7.5 mg)
Study: 25898052
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (2.5 mg)
Study: 22007909
Drug: 10% urea-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea-based lotion (Ureadin Rx 10)
Study: 22007909
Drug: Glycerol-based emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-based emollient cream (Dexeryl)
Study: 16490584
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Sensibit)
Study: 16490584
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Clarityne)
Study: 12499977
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antithrombin (AT group)
Study: 12499977
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (nonAT group)
Study: 12832314
Drug: Repaglinide/metformin
Normalized name: repaglinide/metformin HCl 1 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide/metformin
Study: 12832314
Drug: Nateglinide/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide/metformin
Study: 11234559
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcipotriol and diflucortolone valerate ointment
Study: 11234559
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (calcipotriol and diflucortolone valerate)
Study: 6491703
Drug: 5-fluorouracil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (15 mg/kg by rapid intravenous injection X 3) plus radiation (3,750 rad in 24 fractions)
Study: 6491703
Drug: No surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgical adjuvant therapy
Study: 6491703
Drug: Treatment refusal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment refusal
Study: 29862619
Drug: ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipragliflozin 50 mg/day
Study: 25237981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AAB and ibuprofen
Study: 20883560
Drug: ATG-Fresenius plus
Normalized name: ATG-Fresenius S
DrugBank: ATG-Fresenius S (DB05320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-Fresenius plus reduced-dose tacrolimus monotherapy
Study: 20883560
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus plus steroids
Study: 16046455
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone administration (GH) 6 IU/day for 2 weeks
Study: 12153969
Drug: Once-daily 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 2.5 mg rhDNase
Study: 12153969
Drug: Alternate-day 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day 2.5 mg rhDNase
Study: 12153969
Drug: Twice-daily 7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily 7% HS
Study: 12153969
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of daily rhDNase with alternate-day rhDNase and HS
Study: 18328120
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/HCTZ 25 mg
Study: 10915394
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg/HCTZ 25 mg
Study: 7872282
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg q.i.d.
Study: 7872282
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg q.i.d.
Study: 2370014
Drug: Cyclosporin 5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 5-7.5 mg/kg/day
Study: 6849742
Drug: Practolol 200
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 200 mg
Study: 31332775
Drug: Single-injection Erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection Erector Spinae Plane Block (ESPB)
Study: 31332775
Drug: Multiple-injection Costotransverse
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-injection Costotransverse Block (MICB)
Study: 31332775
Drug: Single-injection Thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection Thoracic Paravertebral Block (TPVB)
Study: 31332775
Drug: Multiple-injection Thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-injection Thoracic Paravertebral Block (TPVB)
Study: 28452195
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 µg/kg/day)
Study: 18337551
Drug: Intravenous mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mesna 5 mg/kg thrice weekly before dialysis
Study: 3234474
Drug: Fenoterol 2.5
Normalized name: fenoterol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 2.5 mg t.d.s.
Study: 28741272
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of 11.25 mg hyperbaric bupivacaine with morphine 150 µg and fentanyl 15 µg
Study: 28741272
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of 15 mg hyperbaric bupivacaine with morphine 150 µg and fentanyl 15 µg
Study: 23349254
Drug: Biostimine (Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostimine (Aloe arborescens Mill. extract), 1 ampoule once daily for 4 weeks
Study: 19650798
Drug: Rocuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium infusion at CSM
Study: 19650798
Drug: Rocuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium infusion at APM
Study: 14663908
Drug: Intratumoral chemotherapy
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral chemotherapy with cytostatic drugs and prednisolone during bronchofibroscopy
Study: 8999375
Drug: Constant propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Constant propofol infusion of 200 micrograms/kg/min during the pre-bypass period and fentanyl boluses of 1 mg when required (PH Group)
Study: 8999375
Drug: Variable propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable propofol infusion (from 43.09 to 22.42 micrograms/kg/min) during the pre-bypass period and a fixed infusion of 10.47 micrograms/kg/min during the post-bypass period (PL Group)
Study: 8999375
Drug: 1% isoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% isoflurane administration throughout the intraoperative period (F Group)
Study: 28850378
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray (V)
Study: 28850378
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (S)
Study: 23311540
Drug: 8 gm
Normalized name: Cola 38 GM/30 ML Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 gm MgSO4 (two 4 gm doses q4H) (Group B, 8 patients)
Study: 23311540
Drug: 12 gm
Normalized name: Carimune 12 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 gm MgSO4 (three 4 gm doses q4H) (Group C, 8 patients)
Study: 23311540
Drug: 16 gm
Normalized name: magnesium citrate 16 GM Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 gm MgSO4 (four 4 gm doses q4H) (Group D, 8 patients)
Study: 21711463
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid (reference resurfacing molecule)
Study: 16886975
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 4,000 mg over 15 min
Study: 16886975
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 2,500 mg over 5 min
Study: 16886975
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) administered IV
Study: 15617949
Drug: Blind group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind group (active drug and placebo)
Study: 15617949
Drug: Nonblind group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonblind group (active drug and no treatment)
Study: 11020259
Drug: Bifidobacterium longum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium longum, Lactobacillus acidophilus and oligofructose (c.1011 cfu of B. longum BB 536 and L. acidophilus NCFB 1748 and 15 g oligofructose daily)
Study: 8246751
Drug: Theophylline slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline slow-release tablet
Study: 7049013
Drug: Theophylline syrup
Normalized name: Theophylline Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline syrup
Study: 3898281
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg administered subcutaneously)
Study: 24083754
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cyclophosphamide six-cycle therapy (TC6)
Study: 21459680
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg
Study: 21459680
Drug: Celecoxib 50
Normalized name: celecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 50 mg
Study: 21459680
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg followed by 50 mg
Study: 18366084
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment using the dynamic cooling device (DCD)
Study: 9414975
Drug: Fedotozine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedotozine 30 mg three times daily
Study: 8503552
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of allergen-antibody complexes (Group A)
Study: 8503552
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of allergen-antibody complexes (Group B)
Study: 7612555
Drug: Intraoperative application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes)
Study: 25237
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg etilefrin
Study: 25237
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dihydroergotamine
Study: 31429006
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg once/day) in addition to conventional therapy
Study: 25284704
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 μg oral dose) with STN‐DBS ON
Study: 25284704
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 μg oral dose) with STN‐DBS OFF
Study: 16902083
Drug: Hospital clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital clinic-based chemotherapy
Study: 11130089
Drug: Dinoproston, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoproston, 0.5 mg intracervically every 12 hours for a maximum of 24 hours
Study: 8339645
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (6 g MgSO4 i.v. over 16 h)
Study: 3732368
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of beclomethasone dipropionate aerosol
Study: 3732368
Drug: Four-times daily
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-times daily administration of beclomethasone dipropionate aerosol
Study: 22326841
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 60 mg/day